Spiro Rombotis, President and CEO of Cyclacel Pharmaceuticals, Reveals the Secrets to Becoming a Small Company with Huge Potential with Business Review USA
President and CEO of Cyclacel Pharmaceuticals discusses how the company has become a world leader in understanding the biological mechanisms that affect the cancer cell cycle.

SAN DIEGO, CA, May 21, 2011 /24-7PressRelease/ -- In an interview with Business Review USA, Spiro Rombotis, President and CEO of Cyclacel Pharmaceuticals discusses how the company has become a world leader in understanding the biological mechanisms that affect the cancer cell cycle.

Cyclacel is leading the pharmaceutical industry in the development of an oral drug for Acute Myeloid Leukemia (AML) called sapacitabine and another oral drug called seliciclib, which is most advanced in trials of patients with terminal lung cancer. "Very few biotech companies are fortunate to develop a cancer drug that reaches the market. Even fewer get to do it twice," says Rombotis in the interview.

Read the full article here.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals is a drug discovery and development company specializing in cell cycle biology. The discovery of cancer suppressing gene mechanisms and their role were awarded the 2001 Nobel Prize for Medicine. The most famous of these genes, p53, was discovered by Professor David Lane, who founded Cyclacel in 1996. Visit www.cyclacel.com for more information.

Press Release Contact Information:

Philip Diehl
Business Review USA
Marketing Manager
5901 Priestly Drive #300
Carlsbad, CA
United States 92008
Voice: 760-827-7800
Website: Visit Our Website